PROCEPT BioRobotics (NASDAQ:PRCT) vs. SeaStar Medical (NASDAQ:ICU) Head to Head Comparison

SeaStar Medical (NASDAQ:ICU) and PROCEPT BioRobotics (NASDAQ:PRCT) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership.

Earnings & Valuation

This table compares SeaStar Medical and PROCEPT BioRobotics’ top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SeaStar Medical	N/A	N/A	-$23.01 million	($1.21)	-0.33
PROCEPT BioRobotics	$136.19 million	18.78	-$105.90 million	($2.24)	-22.41

SeaStar Medical has higher earnings, but lower revenue than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than SeaStar Medical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares SeaStar Medical and PROCEPT BioRobotics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SeaStar Medical	N/A	N/A	-961.93%
PROCEPT BioRobotics	-77.75%	-46.59%	-30.63%

Risk & Volatility

SeaStar Medical has a beta of -1.18, indicating that its share price is 218% less volatile than the S&P 500. Comparatively, PROCEPT BioRobotics has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for SeaStar Medical and PROCEPT BioRobotics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SeaStar Medical	0	0	0	0	N/A
PROCEPT BioRobotics	0	0	6	0	3.00

SeaStar Medical presently has a consensus price target of $0.00, suggesting a potential downside of 100.00%. PROCEPT BioRobotics has a consensus price target of $45.60, suggesting a potential downside of 9.15%. Given PROCEPT BioRobotics’ higher possible upside, analysts plainly believe PROCEPT BioRobotics is more favorable than SeaStar Medical.

Insider and Institutional Ownership

1.7% of SeaStar Medical shares are owned by institutional investors. Comparatively, 89.5% of PROCEPT BioRobotics shares are owned by institutional investors. 4.5% of SeaStar Medical shares are owned by insiders. Comparatively, 19.6% of PROCEPT BioRobotics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

PROCEPT BioRobotics beats SeaStar Medical on 7 of the 12 factors compared between the two stocks.

About SeaStar Medical

SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome. SeaStar Medical Holding Corporation is headquartered in Denver, Colorado.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.